FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3119941821> ?p ?o ?g. }

• W3119941821 endingPage "e23582" @default.
• W3119941821 startingPage "e23582" @default.
• W3119941821 abstract "COVID-19 is causing a high influx of patients suffering from serious respiratory complications leading the necessity to find effective therapies. These patients seem to present with cytokine perturbation and high levels of IL6. Tocilizumab and sarilumab could be effective in this condition. We retrospectively collected data about 112 consecutive hospitalized in a single center. Fifty (IL6 group) treated with tocilizumab (8 mg/kg intravenously [IV], 2 infusions 12 hours apart) or sarilumab 400 mg IV once and 62 treated with the standard of care but not anti-cytokine drugs (CONTROL group). To determine whether anti-IL6 drugs are effective in improving prognosis and reducing hospitalization times and mortality in COVID-19 pneumonia. To date 84% (42/50) of IL6 group patients have already been discharged and only 2/50 are still recovered and intubated in intensive care. Six/fifty patients (12%) died: 5/6 due to severe respiratory failure within a framework of severe acute respiratory distress syndrome (ARDS), 1 suffered an acute myocardial infarction, and 1 died of massive pulmonary thromboembolism. There were no adverse treatment events or infectious complications. Compared to the CONTROL group they showed a lower mortality rate (12% versus 43%), for the same number of complications and days of hospitalization. Anti-IL6 drugs seem to be effective in the treatment of medium to severe forms of COVID-19 pneumonia reducing the risk of mortality due to multi-organ failure, acting at the systemic level and reducing inflammation levels and therefore microvascular complications. However, it is essential to identify the best time for treatment, which, if delayed, is rendered useless as well as counterproductive. Further studies and ongoing clinical trials will help us to better define patients eligible as candidates for more aggressive intervention." @default.
• W3119941821 created "2021-01-18" @default.
• W3119941821 creator A5001320859 @default.
• W3119941821 creator A5009782649 @default.
• W3119941821 creator A5016486676 @default.
• W3119941821 creator A5018854701 @default.
• W3119941821 creator A5030055327 @default.
• W3119941821 creator A5054771692 @default.
• W3119941821 creator A5055292769 @default.
• W3119941821 creator A5056646398 @default.
• W3119941821 creator A5057687054 @default.
• W3119941821 creator A5081736345 @default.
• W3119941821 creator A5083600202 @default.
• W3119941821 creator A5086297270 @default.
• W3119941821 creator A5007838065 @default.
• W3119941821 date "2021-01-08" @default.
• W3119941821 modified "2023-10-03" @default.
• W3119941821 title "Anti-IL6 treatment of serious COVID-19 disease" @default.
• W3119941821 cites W1800085677 @default.
• W3119941821 cites W2765166506 @default.
• W3119941821 cites W2805472045 @default.
• W3119941821 cites W2952260713 @default.
• W3119941821 cites W3008372187 @default.
• W3119941821 cites W3012421327 @default.
• W3119941821 cites W3014306106 @default.
• W3119941821 cites W3015542196 @default.
• W3119941821 cites W3022970339 @default.
• W3119941821 cites W3031663595 @default.
• W3119941821 doi "https://doi.org/10.1097/md.0000000000023582" @default.
• W3119941821 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7793456" @default.
• W3119941821 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33429732" @default.
• W3119941821 hasPublicationYear "2021" @default.
• W3119941821 type Work @default.
• W3119941821 sameAs 3119941821 @default.
• W3119941821 citedByCount "34" @default.
• W3119941821 countsByYear W31199418212021 @default.
• W3119941821 countsByYear W31199418212022 @default.
• W3119941821 countsByYear W31199418212023 @default.
• W3119941821 crossrefType "journal-article" @default.
• W3119941821 hasAuthorship W3119941821A5001320859 @default.
• W3119941821 hasAuthorship W3119941821A5007838065 @default.
• W3119941821 hasAuthorship W3119941821A5009782649 @default.
• W3119941821 hasAuthorship W3119941821A5016486676 @default.
• W3119941821 hasAuthorship W3119941821A5018854701 @default.
• W3119941821 hasAuthorship W3119941821A5030055327 @default.
• W3119941821 hasAuthorship W3119941821A5054771692 @default.
• W3119941821 hasAuthorship W3119941821A5055292769 @default.
• W3119941821 hasAuthorship W3119941821A5056646398 @default.
• W3119941821 hasAuthorship W3119941821A5057687054 @default.
• W3119941821 hasAuthorship W3119941821A5081736345 @default.
• W3119941821 hasAuthorship W3119941821A5083600202 @default.
• W3119941821 hasAuthorship W3119941821A5086297270 @default.
• W3119941821 hasBestOaLocation W31199418211 @default.
• W3119941821 hasConcept C126322002 @default.
• W3119941821 hasConcept C197934379 @default.
• W3119941821 hasConcept C2776348555 @default.
• W3119941821 hasConcept C2776888751 @default.
• W3119941821 hasConcept C2777178219 @default.
• W3119941821 hasConcept C2777714996 @default.
• W3119941821 hasConcept C2777914695 @default.
• W3119941821 hasConcept C2779134260 @default.
• W3119941821 hasConcept C2780850621 @default.
• W3119941821 hasConcept C3008058167 @default.
• W3119941821 hasConcept C524204448 @default.
• W3119941821 hasConcept C71924100 @default.
• W3119941821 hasConceptScore W3119941821C126322002 @default.
• W3119941821 hasConceptScore W3119941821C197934379 @default.
• W3119941821 hasConceptScore W3119941821C2776348555 @default.
• W3119941821 hasConceptScore W3119941821C2776888751 @default.
• W3119941821 hasConceptScore W3119941821C2777178219 @default.
• W3119941821 hasConceptScore W3119941821C2777714996 @default.
• W3119941821 hasConceptScore W3119941821C2777914695 @default.
• W3119941821 hasConceptScore W3119941821C2779134260 @default.
• W3119941821 hasConceptScore W3119941821C2780850621 @default.
• W3119941821 hasConceptScore W3119941821C3008058167 @default.
• W3119941821 hasConceptScore W3119941821C524204448 @default.
• W3119941821 hasConceptScore W3119941821C71924100 @default.
• W3119941821 hasIssue "1" @default.
• W3119941821 hasLocation W31199418211 @default.
• W3119941821 hasLocation W31199418212 @default.
• W3119941821 hasLocation W31199418213 @default.
• W3119941821 hasLocation W31199418214 @default.
• W3119941821 hasLocation W31199418215 @default.
• W3119941821 hasOpenAccess W3119941821 @default.
• W3119941821 hasPrimaryLocation W31199418211 @default.
• W3119941821 hasRelatedWork W3021625674 @default.
• W3119941821 hasRelatedWork W3036565291 @default.
• W3119941821 hasRelatedWork W3037799957 @default.
• W3119941821 hasRelatedWork W3043733906 @default.
• W3119941821 hasRelatedWork W3092370030 @default.
• W3119941821 hasRelatedWork W3092879025 @default.
• W3119941821 hasRelatedWork W3132427123 @default.
• W3119941821 hasRelatedWork W3200204127 @default.
• W3119941821 hasRelatedWork W4223889410 @default.
• W3119941821 hasRelatedWork W4361005700 @default.
• W3119941821 hasVolume "100" @default.
• W3119941821 isParatext "false" @default.
• W3119941821 isRetracted "false" @default.

• next